Contact number:
400 007 5658
-
R&D
With the R&D and manufacture of controlled-release drug products as the core business, Anbison focuses on development of high-end controlled-release dosage forms and finished dosage forms that are inherently difficult to manufacture. Meanwhile, we are actively expanding to 505b(2) drugs and complex long-acting injectables.
To learn more, please slide the window left and right
| Product Name | Status | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Compound Sodium Valproate and Valproic Acid Sustained Release Tablets | Submitted to NMPA | ||||
| Exemestane Tablets | Submitted to NMPA | ||||
| Flurbiprofen Cataplasms | Submitted to NMPA | ||||
| Amlodipine and Benazepril Hydrochloride Capsules | Submitted to NMPA | ||||
| Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets | Submitted to NMPA | ||||
| Mesalazine Suppositories | Submitted to NMPA | ||||
| Tafluprost Eye Drops | Submitted to NMPA | ||||
| Cyclosporin Eye Drops/cyclosporine ophthalmic emulsion（Ⅱ） | Submitted to FDA | ||||
| Perindopril arginine and amlodipine besylate tablets | Submitted to NMPA | ||||
| Eperisone Hydrochloride Tablets | Submitted to NMPA | ||||
| Metformin Hydrochloride and Glipizide Tablets | Submitted to NMPA | ||||
| Nalmefene Hydrochloride Injection | Submitted to NMPA | ||||
| Tacrolimus Sustained-release Capsules | Submitted to NMPA | ||||
| Toremifene Citrate Tablets | Submitted to NMPA | ||||
| Dapagliflozin and Metformin Hydrochloride Extended-release Tablets | Submitted to NMPA |